nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.335	0.52	CbGbCtD
Gefitinib—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.309	0.48	CbGbCtD
Gefitinib—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00589	0.0469	CcSEcCtD
Gefitinib—ERBB3—peripheral nervous system—amyotrophic lateral sclerosis	0.00586	0.0733	CbGeAlD
Gefitinib—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00511	0.0408	CcSEcCtD
Gefitinib—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00483	0.0385	CcSEcCtD
Gefitinib—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00468	0.0373	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00436	0.0347	CcSEcCtD
Gefitinib—Lapatinib—ERBB4—amyotrophic lateral sclerosis	0.00425	0.397	CrCbGaD
Gefitinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.0042	0.0335	CcSEcCtD
Gefitinib—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00402	0.032	CcSEcCtD
Gefitinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0309	CcSEcCtD
Gefitinib—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00385	0.0307	CcSEcCtD
Gefitinib—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00314	0.025	CcSEcCtD
Gefitinib—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0241	CcSEcCtD
Gefitinib—Afatinib—ERBB4—amyotrophic lateral sclerosis	0.00301	0.281	CrCbGaD
Gefitinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.0029	0.0231	CcSEcCtD
Gefitinib—SBK1—medulla oblongata—amyotrophic lateral sclerosis	0.00257	0.0321	CbGeAlD
Gefitinib—MAP2K5—hindbrain—amyotrophic lateral sclerosis	0.00236	0.0296	CbGeAlD
Gefitinib—SBK1—spinal cord—amyotrophic lateral sclerosis	0.00229	0.0286	CbGeAlD
Gefitinib—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0182	CcSEcCtD
Gefitinib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0181	CcSEcCtD
Gefitinib—ERBB3—embryo—amyotrophic lateral sclerosis	0.00214	0.0268	CbGeAlD
Gefitinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00201	0.016	CcSEcCtD
Gefitinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00196	0.0156	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00194	0.0155	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0152	CcSEcCtD
Gefitinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00183	0.0146	CcSEcCtD
Gefitinib—SBK1—cerebellum—amyotrophic lateral sclerosis	0.00181	0.0227	CbGeAlD
Gefitinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00169	0.0134	CcSEcCtD
Gefitinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0133	CcSEcCtD
Gefitinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0132	CcSEcCtD
Gefitinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0132	CcSEcCtD
Gefitinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00162	0.0129	CcSEcCtD
Gefitinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0126	CcSEcCtD
Gefitinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0125	CcSEcCtD
Gefitinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0125	CcSEcCtD
Gefitinib—Iloperidone—SIGMAR1—amyotrophic lateral sclerosis	0.00156	0.146	CrCbGaD
Gefitinib—EPHA6—nervous system—amyotrophic lateral sclerosis	0.00151	0.0189	CbGeAlD
Gefitinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.0015	0.012	CcSEcCtD
Gefitinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0119	CcSEcCtD
Gefitinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0119	CcSEcCtD
Gefitinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0117	CcSEcCtD
Gefitinib—SBK1—brain—amyotrophic lateral sclerosis	0.00147	0.0184	CbGeAlD
Gefitinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0117	CcSEcCtD
Gefitinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0117	CcSEcCtD
Gefitinib—HIPK4—brain—amyotrophic lateral sclerosis	0.00146	0.0182	CbGeAlD
Gefitinib—EPHA6—central nervous system—amyotrophic lateral sclerosis	0.00145	0.0182	CbGeAlD
Gefitinib—CSNK1E—medulla oblongata—amyotrophic lateral sclerosis	0.00142	0.0177	CbGeAlD
Gefitinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00141	0.0112	CcSEcCtD
Gefitinib—IRAK4—medulla oblongata—amyotrophic lateral sclerosis	0.0014	0.0175	CbGeAlD
Gefitinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0111	CcSEcCtD
Gefitinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00139	0.011	CcSEcCtD
Gefitinib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.00137	0.0171	CbGeAlD
Gefitinib—MAP2K5—brainstem—amyotrophic lateral sclerosis	0.00135	0.0169	CbGeAlD
Gefitinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0108	CcSEcCtD
Gefitinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0107	CcSEcCtD
Gefitinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00133	0.0106	CcSEcCtD
Gefitinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0105	CcSEcCtD
Gefitinib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.00132	0.0165	CbGeAlD
Gefitinib—Bosutinib—ERBB4—amyotrophic lateral sclerosis	0.00131	0.122	CrCbGaD
Gefitinib—MKNK2—medulla oblongata—amyotrophic lateral sclerosis	0.0013	0.0163	CbGeAlD
Gefitinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0104	CcSEcCtD
Gefitinib—MKNK1—medulla oblongata—amyotrophic lateral sclerosis	0.00128	0.0161	CbGeAlD
Gefitinib—CHEK2—brain—amyotrophic lateral sclerosis	0.00128	0.0161	CbGeAlD
Gefitinib—CSNK1E—spinal cord—amyotrophic lateral sclerosis	0.00126	0.0158	CbGeAlD
Gefitinib—IRAK4—spinal cord—amyotrophic lateral sclerosis	0.00124	0.0156	CbGeAlD
Gefitinib—ERBB3—spinal cord—amyotrophic lateral sclerosis	0.00122	0.0153	CbGeAlD
Gefitinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00957	CcSEcCtD
Gefitinib—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00946	CcSEcCtD
Gefitinib—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00934	CcSEcCtD
Gefitinib—MKNK2—spinal cord—amyotrophic lateral sclerosis	0.00116	0.0145	CbGeAlD
Gefitinib—EPHA6—brain—amyotrophic lateral sclerosis	0.00115	0.0144	CbGeAlD
Gefitinib—MKNK1—spinal cord—amyotrophic lateral sclerosis	0.00114	0.0143	CbGeAlD
Gefitinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00903	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00875	CcSEcCtD
Gefitinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00862	CcSEcCtD
Gefitinib—CSNK1E—nervous system—amyotrophic lateral sclerosis	0.00106	0.0133	CbGeAlD
Gefitinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00839	CcSEcCtD
Gefitinib—IRAK4—nervous system—amyotrophic lateral sclerosis	0.00105	0.0131	CbGeAlD
Gefitinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.00105	0.0131	CbGeAlD
Gefitinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00831	CcSEcCtD
Gefitinib—EGFR—cerebellum—amyotrophic lateral sclerosis	0.00104	0.013	CbGeAlD
Gefitinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00829	CcSEcCtD
Gefitinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00827	CcSEcCtD
Gefitinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00821	CcSEcCtD
Gefitinib—ERBB3—nervous system—amyotrophic lateral sclerosis	0.00103	0.0129	CbGeAlD
Gefitinib—CSNK1E—central nervous system—amyotrophic lateral sclerosis	0.00103	0.0128	CbGeAlD
Gefitinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00805	CcSEcCtD
Gefitinib—IRAK4—central nervous system—amyotrophic lateral sclerosis	0.00101	0.0126	CbGeAlD
Gefitinib—CSNK1E—cerebellum—amyotrophic lateral sclerosis	0.001	0.0125	CbGeAlD
Gefitinib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000991	0.0079	CcSEcCtD
Gefitinib—ERBB3—central nervous system—amyotrophic lateral sclerosis	0.000989	0.0124	CbGeAlD
Gefitinib—IRAK4—cerebellum—amyotrophic lateral sclerosis	0.000986	0.0123	CbGeAlD
Gefitinib—MKNK2—nervous system—amyotrophic lateral sclerosis	0.000977	0.0122	CbGeAlD
Gefitinib—ERBB3—cerebellum—amyotrophic lateral sclerosis	0.000967	0.0121	CbGeAlD
Gefitinib—MKNK1—nervous system—amyotrophic lateral sclerosis	0.000965	0.0121	CbGeAlD
Gefitinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000945	0.00753	CcSEcCtD
Gefitinib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.000944	0.0118	CbGeAlD
Gefitinib—MKNK2—central nervous system—amyotrophic lateral sclerosis	0.000941	0.0118	CbGeAlD
Gefitinib—MKNK1—central nervous system—amyotrophic lateral sclerosis	0.000929	0.0116	CbGeAlD
Gefitinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00735	CcSEcCtD
Gefitinib—IRAK1—cerebellum—amyotrophic lateral sclerosis	0.000919	0.0115	CbGeAlD
Gefitinib—MKNK2—cerebellum—amyotrophic lateral sclerosis	0.000919	0.0115	CbGeAlD
Gefitinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000915	0.0073	CcSEcCtD
Gefitinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000914	0.00729	CcSEcCtD
Gefitinib—MKNK1—cerebellum—amyotrophic lateral sclerosis	0.000908	0.0114	CbGeAlD
Gefitinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000907	0.00723	CcSEcCtD
Gefitinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000907	0.00723	CcSEcCtD
Gefitinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00691	CcSEcCtD
Gefitinib—EGFR—brain—amyotrophic lateral sclerosis	0.000846	0.0106	CbGeAlD
Gefitinib—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000842	0.00671	CcSEcCtD
Gefitinib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.000842	0.0105	CbGeAlD
Gefitinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000838	0.00668	CcSEcCtD
Gefitinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000838	0.00668	CcSEcCtD
Gefitinib—CSNK1E—brain—amyotrophic lateral sclerosis	0.000814	0.0102	CbGeAlD
Gefitinib—IRAK4—brain—amyotrophic lateral sclerosis	0.000801	0.01	CbGeAlD
Gefitinib—STK10—nervous system—amyotrophic lateral sclerosis	0.000794	0.00994	CbGeAlD
Gefitinib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000788	0.00986	CbGeAlD
Gefitinib—ERBB3—brain—amyotrophic lateral sclerosis	0.000785	0.00983	CbGeAlD
Gefitinib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000781	0.00623	CcSEcCtD
Gefitinib—STK10—central nervous system—amyotrophic lateral sclerosis	0.000765	0.00957	CbGeAlD
Gefitinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000761	0.00606	CcSEcCtD
Gefitinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00598	CcSEcCtD
Gefitinib—STK10—cerebellum—amyotrophic lateral sclerosis	0.000748	0.00936	CbGeAlD
Gefitinib—MKNK2—brain—amyotrophic lateral sclerosis	0.000747	0.00935	CbGeAlD
Gefitinib—IRAK1—brain—amyotrophic lateral sclerosis	0.000747	0.00935	CbGeAlD
Gefitinib—MKNK1—brain—amyotrophic lateral sclerosis	0.000737	0.00923	CbGeAlD
Gefitinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000725	0.00578	CcSEcCtD
Gefitinib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.000709	0.00888	CbGeAlD
Gefitinib—ORM1—spinal cord—amyotrophic lateral sclerosis	0.000684	0.00856	CbGeAlD
Gefitinib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000683	0.00855	CbGeAlD
Gefitinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00537	CcSEcCtD
Gefitinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000669	0.00533	CcSEcCtD
Gefitinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000668	0.00532	CcSEcCtD
Gefitinib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000668	0.00836	CbGeAlD
Gefitinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00063	0.00502	CcSEcCtD
Gefitinib—STK10—brain—amyotrophic lateral sclerosis	0.000607	0.0076	CbGeAlD
Gefitinib—Vandetanib—VEGFA—amyotrophic lateral sclerosis	0.00058	0.0542	CrCbGaD
Gefitinib—ORM1—nervous system—amyotrophic lateral sclerosis	0.000576	0.00721	CbGeAlD
Gefitinib—ORM1—central nervous system—amyotrophic lateral sclerosis	0.000555	0.00694	CbGeAlD
Gefitinib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000542	0.00679	CbGeAlD
Gefitinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000459	0.00575	CbGeAlD
Gefitinib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000452	0.00565	CbGeAlD
Gefitinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.00041	0.00513	CbGeAlD
Gefitinib—ALB—brain—amyotrophic lateral sclerosis	0.000386	0.00483	CbGeAlD
Gefitinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000354	0.00444	CbGeAlD
Gefitinib—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000328	0.0041	CbGeAlD
Gefitinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000325	0.00406	CbGeAlD
Gefitinib—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000315	0.00395	CbGeAlD
Gefitinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000264	0.0033	CbGeAlD
Gefitinib—CYP1A1—brain—amyotrophic lateral sclerosis	0.00025	0.00313	CbGeAlD
Gefitinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00024	0.00301	CbGeAlD
Gefitinib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000237	0.00296	CbGeAlD
Gefitinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000231	0.0029	CbGeAlD
Gefitinib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000228	0.00285	CbGeAlD
Gefitinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000226	0.00283	CbGeAlD
Gefitinib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000223	0.00279	CbGeAlD
Gefitinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000202	0.00253	CbGeAlD
Gefitinib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000181	0.00226	CbGeAlD
Gefitinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00017	0.00213	CbGeAlD
Gefitinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000164	0.00205	CbGeAlD
Gefitinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.00016	0.002	CbGeAlD
Gefitinib—ABCB1—brain—amyotrophic lateral sclerosis	0.00013	0.00163	CbGeAlD
Gefitinib—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	3.65e-05	0.000262	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	3.65e-05	0.000262	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.61e-05	0.000259	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.6e-05	0.000259	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.6e-05	0.000259	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ERBB4—amyotrophic lateral sclerosis	3.57e-05	0.000257	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.56e-05	0.000256	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	3.56e-05	0.000256	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	3.56e-05	0.000256	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.54e-05	0.000255	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	3.53e-05	0.000254	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	3.52e-05	0.000253	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CASP9—amyotrophic lateral sclerosis	3.48e-05	0.00025	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	3.47e-05	0.000249	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.46e-05	0.000248	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.46e-05	0.000248	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	3.42e-05	0.000245	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	3.41e-05	0.000245	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.4e-05	0.000244	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40LG—amyotrophic lateral sclerosis	3.36e-05	0.000241	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.36e-05	0.000241	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.36e-05	0.000241	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—APOE—amyotrophic lateral sclerosis	3.35e-05	0.000241	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	3.35e-05	0.00024	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	3.34e-05	0.00024	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	3.33e-05	0.000239	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.33e-05	0.000239	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.33e-05	0.000239	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ERBB4—amyotrophic lateral sclerosis	3.3e-05	0.000237	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	3.28e-05	0.000236	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	3.26e-05	0.000234	CbGpPWpGaD
Gefitinib—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	3.25e-05	0.000233	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.24e-05	0.000233	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.23e-05	0.000232	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.22e-05	0.000232	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.21e-05	0.000231	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.16e-05	0.000227	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.16e-05	0.000227	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.15e-05	0.000226	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.14e-05	0.000225	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—TP53—amyotrophic lateral sclerosis	3.11e-05	0.000223	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.1e-05	0.000223	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.1e-05	0.000223	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	3.09e-05	0.000222	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.07e-05	0.00022	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	3.04e-05	0.000219	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.04e-05	0.000218	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.03e-05	0.000218	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.03e-05	0.000217	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.02e-05	0.000217	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.02e-05	0.000217	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.98e-05	0.000214	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—C3—amyotrophic lateral sclerosis	2.97e-05	0.000213	CbGpPWpGaD
Gefitinib—EGFR—Disease—CST3—amyotrophic lateral sclerosis	2.95e-05	0.000212	CbGpPWpGaD
Gefitinib—MKNK1—Disease—PTGS2—amyotrophic lateral sclerosis	2.95e-05	0.000212	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	2.95e-05	0.000212	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.94e-05	0.000211	CbGpPWpGaD
Gefitinib—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	2.94e-05	0.000211	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	2.92e-05	0.000209	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	2.89e-05	0.000208	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.88e-05	0.000207	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.86e-05	0.000206	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.85e-05	0.000205	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.85e-05	0.000205	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.85e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—C3—amyotrophic lateral sclerosis	2.84e-05	0.000204	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.84e-05	0.000204	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.83e-05	0.000203	CbGpPWpGaD
Gefitinib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.82e-05	0.000203	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.81e-05	0.000202	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.8e-05	0.000201	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.8e-05	0.000201	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.79e-05	0.0002	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.73e-05	0.000196	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	2.73e-05	0.000196	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.71e-05	0.000195	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.7e-05	0.000194	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.68e-05	0.000193	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.67e-05	0.000192	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.66e-05	0.000191	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	2.66e-05	0.000191	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.64e-05	0.000189	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.61e-05	0.000188	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.6e-05	0.000187	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.59e-05	0.000186	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.57e-05	0.000185	CbGpPWpGaD
Gefitinib—ERBB3—Disease—APOE—amyotrophic lateral sclerosis	2.55e-05	0.000183	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.52e-05	0.000181	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.52e-05	0.000181	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.52e-05	0.000181	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.49e-05	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.48e-05	0.000178	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—C3—amyotrophic lateral sclerosis	2.47e-05	0.000178	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.45e-05	0.000176	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.44e-05	0.000175	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ATF1—amyotrophic lateral sclerosis	2.44e-05	0.000175	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.43e-05	0.000174	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.41e-05	0.000173	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.4e-05	0.000172	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.39e-05	0.000171	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.36e-05	0.00017	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.35e-05	0.000169	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CASP9—amyotrophic lateral sclerosis	2.33e-05	0.000167	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.31e-05	0.000166	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—amyotrophic lateral sclerosis	2.3e-05	0.000165	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.29e-05	0.000165	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.26e-05	0.000163	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.25e-05	0.000162	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.25e-05	0.000162	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.25e-05	0.000161	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.23e-05	0.00016	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.21e-05	0.000159	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.19e-05	0.000158	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.19e-05	0.000158	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.17e-05	0.000156	CbGpPWpGaD
Gefitinib—EGFR—Disease—CASP9—amyotrophic lateral sclerosis	2.15e-05	0.000154	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.06e-05	0.000148	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.06e-05	0.000148	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	2.06e-05	0.000148	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.05e-05	0.000147	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.05e-05	0.000147	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.01e-05	0.000144	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2e-05	0.000144	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.99e-05	0.000143	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB4—amyotrophic lateral sclerosis	1.99e-05	0.000143	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.96e-05	0.000141	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.95e-05	0.00014	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.94e-05	0.000139	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.92e-05	0.000138	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.92e-05	0.000138	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.92e-05	0.000138	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.87e-05	0.000134	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—amyotrophic lateral sclerosis	1.87e-05	0.000134	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.87e-05	0.000134	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.85e-05	0.000133	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.85e-05	0.000133	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.84e-05	0.000133	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.84e-05	0.000132	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.84e-05	0.000132	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.82e-05	0.000131	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.81e-05	0.00013	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.81e-05	0.00013	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.81e-05	0.00013	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.8e-05	0.000129	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.8e-05	0.000129	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.79e-05	0.000128	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.77e-05	0.000127	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.75e-05	0.000126	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—amyotrophic lateral sclerosis	1.75e-05	0.000126	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.74e-05	0.000125	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.7e-05	0.000122	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.69e-05	0.000121	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.69e-05	0.000121	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.68e-05	0.000121	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.68e-05	0.000121	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.68e-05	0.000121	CbGpPWpGaD
Gefitinib—EGFR—Immune System—C3—amyotrophic lateral sclerosis	1.65e-05	0.000119	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.63e-05	0.000117	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.62e-05	0.000116	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.6e-05	0.000115	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.59e-05	0.000114	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.58e-05	0.000113	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.54e-05	0.000111	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.53e-05	0.00011	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.53e-05	0.00011	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.51e-05	0.000109	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.5e-05	0.000108	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.49e-05	0.000107	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.49e-05	0.000107	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.48e-05	0.000106	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.48e-05	0.000106	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.47e-05	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Disease—APOE—amyotrophic lateral sclerosis	1.42e-05	0.000102	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.41e-05	0.000101	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.4e-05	0.0001	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.39e-05	0.0001	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.38e-05	9.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.38e-05	9.92e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.35e-05	9.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.32e-05	9.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.29e-05	9.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.27e-05	9.1e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.26e-05	9.05e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.23e-05	8.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.23e-05	8.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	8.69e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.2e-05	8.63e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.18e-05	8.47e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.16e-05	8.31e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.14e-05	8.17e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.11e-05	8.01e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.11e-05	7.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.11e-05	7.97e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.07e-05	7.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.07e-05	7.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.06e-05	7.58e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.05e-05	7.56e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1e-05	7.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.95e-06	7.15e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.95e-06	7.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—amyotrophic lateral sclerosis	9.74e-06	7e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.68e-06	6.95e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.65e-06	6.93e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.57e-06	6.87e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.47e-06	6.8e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.47e-06	6.8e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.14e-06	6.57e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	9.13e-06	6.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	9.11e-06	6.54e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.07e-06	6.51e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.95e-06	6.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.64e-06	6.2e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.33e-06	5.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.23e-06	5.91e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.14e-06	5.85e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.03e-06	5.77e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.96e-06	5.72e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.95e-06	5.71e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.62e-06	5.47e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.56e-06	5.43e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.52e-06	5.4e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.49e-06	5.38e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.48e-06	5.37e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.42e-06	5.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.3e-06	5.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.29e-06	5.24e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	6.9e-06	4.95e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.88e-06	4.94e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	6.86e-06	4.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.82e-06	4.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.33e-06	4.55e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	6.16e-06	4.42e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.07e-06	4.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	6.01e-06	4.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.98e-06	4.3e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.66e-06	4.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.61e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.46e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.37e-06	3.86e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.15e-06	3.7e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.9e-06	3.52e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.7e-06	3.38e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.5e-06	3.23e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.22e-06	3.03e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.12e-06	2.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.06e-06	2.92e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.88e-06	2.79e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.85e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.7e-06	2.66e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.54e-06	1.82e-05	CbGpPWpGaD
